Andere Sprachen ImmunityBio, Inc.

Aktien

A2QQ2E

US45256X1037

IBRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
6,1 ^USD	+0,16 %		-4,98 %	+21,51 %

09.05.	ImmunityBio, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
07.05.	ImmunityBio-Aktien steigen nach Abschluss der Herstellung des Wirkstoffs für die Krebsbehandlung	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update	15:14
ImmunityBio - Connecting the Dots of ANKTIVA's Triangle Offense, A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	20.05.
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	17.05.
ImmunityBio: Q1 Earnings Snapshot	10.05.
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	07.05.
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	07.05.
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	07.05.
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	06.05.
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	03.05.
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types	02.05.
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	02.05.
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association	01.05.
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association	30.04.
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	30.04.
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	29.04.
ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval	27.04.
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer	26.04.
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer	25.04.
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	25.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ImmunityBio, Inc.

Aktien

A2QQ2E

US45256X1037

IBRX

Andere Sprachen

Filter